1 results match your criteria: "and the Sequenom Center for Molecular Medicine[Affiliation]"
Circulating Cell-Free DNA to Determine the Fetal RHD Status in All Three Trimesters of Pregnancy.
Obstet Gynecol
December 2016
Departments of Obstetrics and Gynecology at the Baylor College of Medicine, Houston, Texas; The Ohio State University Wexner Medical Center, Columbus, Ohio; Columbia University Medical Center, New York, New York; the University of North Carolina School of Medicine, Chapel Hill, North Carolina; Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania; Tristate Maternal Fetal Medicine Association, Inc, Cincinnati, Ohio; and the Department of Obstetrics, Gynecology and Reproductive Sciences, Icahn School of Medicine at Mt. Sinai, New York, New York; the Departments of Obstetrics and Gynecology at Wayne State University/Detroit Medical Center, Detroit, Michigan; New York Presbyterian Queens and Weill Cornell Medical College, New York, New York; Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Evergreen Hospital, Seattle, Washington; Phoenix Perinatal Associates, Phoenix, Arizona; McGill University, Montréal, Quebec, Canada; the University of British Columbia, Vancouver, Canada; Medical University of South Carolina, Charleston, South Carolina; Spectrum Health Hospitals, Grand Rapids, Michigan; William Beaumont Hospital, Royal Oak, Michigan; Drexel University College of Medicine, Philadelphia, Pennsylvania; and Sequenom, Inc, and the Sequenom Center for Molecular Medicine, San Diego, California.
Objective: To estimate the accuracy of a new assay to determine the fetal RHD status using circulating cell-free DNA.
Methods: This was a prospective, observational study. Maternal blood samples were collected in each trimester of pregnancy in 520 nonalloimmunized RhD-negative patients.